Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease
PR Newswire —
GOTHENBURG, Sweden, Feb. 4, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that it is broadening the development focus...